What a Thorough Medical Evaluation Includes Before Treatment

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: July 15, 2026

Key Takeaways for Safe Peptide Therapy

• A thorough medical evaluation before peptide therapy combines detailed health history, targeted labs, physical assessment, and risk screening to confirm safety and suitability.
• The process at Mirror Plastic Surgery includes a 30–60 minute consultation, full medical and family history review, physical exam, medication check, and shared decision-making.
• Comprehensive baseline labs such as CMP, CBC, lipid panel, HbA1c, thyroid panel, hormone panel, hsCRP, cortisol, and IGF-1 establish objective markers before any protocol begins.
• Key red flags identified during evaluation include active malignancy, medullary thyroid carcinoma history, uncontrolled diabetes, prior pancreatitis, and elevated cortisol levels.
• Schedule your personalized evaluation today to ensure safe, individualized peptide therapy, and get started here.

How Mirror Plastic Surgery Handles Your Peptide Evaluation

At Mirror Plastic Surgery, your peptide evaluation is led by an experienced nurse practitioner and follows a clear, stepwise process that builds a complete clinical picture before any protocol is recommended.

1. 30–60 minute consultation: The initial appointment is reserved exclusively for you. No rushed intake. The provider reviews your concerns, wellness goals, and prior treatment history in depth, whether you are focused on chronic inflammation, weight management, autoimmune conditions, or anti-aging.
2. Full medical and family history: This includes past diagnoses, surgical history, known autoimmune or endocrine conditions, cancer history, and relevant family history. Active malignancy, personal or family history of medullary thyroid carcinoma, and MEN2 syndrome are absolute contraindications for several peptide classes, and only a thorough history reliably identifies them.
3. Physical exam and vitals: Blood pressure, heart rate, and relevant physical findings are documented. For peptides such as PT-141 (Vyleesi), seated blood pressure in both arms is required at baseline because the label notes transient increases in blood pressure.
4. Medication and supplement review: Drug interactions and additive metabolic effects are assessed to prevent dangerous combinations. This screening is critical because certain patient groups face specific risks. Diabetic patients on insulin or sulfonylureas, for example, face an increased risk of severe hypoglycemia when GLP-1 peptides are added without dose adjustment.
5. Shared decision-making: The provider explains the physiological rationale behind each recommendation in plain language. Clients understand not just what they are taking, but why. When a peptide is not yet indicated, the provider says so directly.

Start your comprehensive evaluation at Mirror Plastic Surgery in St. Petersburg, FL.

Core Lab Testing Before You Start Peptides

Laboratory panels form the objective backbone of every responsible peptide protocol. The universal baseline panel recommended before any peptide protocol includes the following markers, each with a clear clinical role.

• Comprehensive Metabolic Panel (CMP): Covers liver enzymes (ALT, AST), kidney function (BUN, creatinine, eGFR), electrolytes, and fasting glucose. Hepatic impairment can produce misleading low IGF-1 levels unrelated to GH deficiency and may require dose adjustment for hepatically metabolized peptides.
• Complete Blood Count (CBC): Establishes reference values for red blood cells, white blood cells, platelets, and hematocrit, and screens for anemia, infection signals, or other blood-cell abnormalities.
• Fasting Lipid Panel (including ApoB and Lp(a)): Guidelines recommend measuring Lp(a) at least once and ApoB to assess cardiovascular risk, so these markers are now standard in comprehensive pre-peptide panels.
• Fasting Glucose, Fasting Insulin, and HOMA-IR: Elevated HOMA-IR indicates insulin resistance that may warrant lower starting doses, dietary adjustments, and closer monitoring during GH peptide therapy.
• HbA1c: Provides a 3-month average of blood sugar levels and is required before GLP-1-class peptides such as GLP-3R compounding.
• Thyroid Panel (TSH, Free T3, Free T4): Hypothyroidism blunts pituitary GH secretion and reduces GH receptor sensitivity. Treating thyroid dysfunction improves peptide therapy outcomes. GH secretagogues can also unmask subclinical hypothyroidism by reducing T4-to-T3 conversion.
• Hormone Panel: Men require total/free testosterone, LH, FSH, estradiol, SHBG, and DHEA-S, and women require estradiol, progesterone, LH, FSH, total testosterone, and DHEA-S because these hormones interact in both directions with the GH/IGF-1 axis.
• hsCRP (High-Sensitivity C-Reactive Protein): This is the primary systemic inflammation marker. An hsCRP baseline below 1 mg/L indicates low cardiovascular risk, while higher values suggest chronic inflammation that many peptide protocols aim to reduce.
• Morning Cortisol: Drawn fasted between 7–9 AM to assess HPA axis status. Chronically elevated cortisol suppresses GH secretion via somatostatin, and levels above 20 μg/dL warrant further investigation before starting peptides.
• IGF-1 (for GH secretagogue protocols): Required for Sermorelin, Ipamorelin, and CJC-1295 protocols. Higher IGF-1 values are associated with increased cancer risk, so age-specific reference ranges apply.
• Lipase and Amylase (for GLP-1-class peptides): Required to screen for pancreatitis risk before initiating GLP-3R or similar compounding protocols.

For protocols involving NAD+, a methylation panel (homocysteine, B12, folate) is added when dosing at high levels. For GHK-Cu (Copper Peptide), baseline serum copper and ceruloplasmin testing is required because Wilson’s disease is an absolute contraindication.

Clinical Red Flags Before Starting Peptide Therapy

A thorough evaluation uses history, labs, and physical findings to uncover contraindications that make certain peptide classes inappropriate or that require protocol changes.

• Active malignancy or cancer history: Growth hormone secretagogues are absolutely contraindicated in patients with active malignancy because they may promote cell proliferation. BPC-157 and TB-500 carry a theoretical risk of supporting tumor growth through angiogenesis.
• Personal or family history of medullary thyroid carcinoma or MEN2: Every FDA-approved GLP-1 agonist carries a boxed warning for medullary thyroid cancer and MEN2, so personal or family history of either condition is an absolute contraindication.
• Uncontrolled diabetes or HOMA-IR above 2.0: GH secretagogue therapy can transiently reduce insulin sensitivity, which can compound pre-existing insulin resistance if metabolic screening is not completed before treatment.
• Prior pancreatitis, gallstone disease, or hypertriglyceridemia above 500 mg/dL: These are documented risk factors for acute pancreatitis with GLP-1 receptor agonist peptides.
• Untreated pituitary tumors: This is an absolute contraindication for GH secretagogues and is identified only through comprehensive history and imaging review.
• Active autoimmune flares: Thymosin alpha-1 should be used cautiously in patients with active autoimmune flares because it enhances T-cell and NK cell activity, which could theoretically worsen autoimmune responses.
• Pregnancy or lactation: This is an absolute contraindication across multiple peptide classes.
• Wilson’s disease: This is an absolute contraindication for GHK-Cu because of copper accumulation risk with chronic use.
• Elevated morning cortisol above 20 μg/dL: This finding warrants further adrenal investigation before starting any GH-axis peptide protocol.

How Evaluation Differs From a Routine Medical Assessment

These terms often sound similar, yet in personalized peptide care the difference affects safety and outcomes.

A standard medical assessment, such as an annual physical, typically involves a general review of systems, basic vitals, and population-level screening labs like a CBC, basic metabolic panel, and lipid panel. It establishes whether a patient is broadly healthy relative to age-matched norms. It does not establish mechanism-specific baselines, identify peptide-class contraindications, or create a framework for ongoing dose calibration.

A thorough medical evaluation for peptide therapy goes substantially further. Peptide therapy protocols require a comprehensive baseline lab panel pulled within two weeks before starting, followed by protocol-specific markers at 4–8 weeks, A1c and metabolic markers at 3 months, and a full panel repeat at 6 months. This creates a rigorous, multi-point monitoring timeline that standard annual physicals do not include. The evaluation is individualized to the specific peptide class, the patient’s metabolic phenotype, and their stated goals, and it produces a written protocol with exact doses, timing, duration, and planned follow-up.

The Mirror Plastic Surgery model reflects this distinction. Ellie’s evaluations continue beyond the first visit. Patients receive direct 24/7 access via text for ongoing support, questions, and protocol adjustments as their physiology responds.

Risks When You Skip a Thorough Evaluation

The documented risks of starting peptide therapy without comprehensive pre-treatment evaluation are specific and serious.

Independent analyses have revealed variability in purity and contamination in gray-market peptide products. Independent testing has shown approximately 40% failure rates in purity or identity testing for grey-market peptides.

Beyond sourcing, skipping evaluation introduces clinical risks that no product label can offset.

• Growth hormone peptide therapy may unmask previously undiagnosed impaired glucose tolerance or diabetes, and without baseline glucose tolerance testing and periodic monitoring, patients face unaddressed metabolic adverse effects.
• In July 2025, two women were hospitalized at a Las Vegas anti-aging festival after receiving peptide injections from a physician, and they developed swollen tongues and breathing difficulties. This event shows that acute adverse reactions can occur even when a physician is present if comprehensive history, physical exam, and lab screening are skipped.
• Serious adverse events have occurred after taking high doses of the unregulated GLP-1 peptide Retatrutide for weight loss without medical oversight.
• Without physician monitoring with bloodwork, subclinical side effects such as elevated liver enzymes and hormonal imbalances can go undetected for months.

Schedule your lab-driven evaluation with Ellie before starting any peptide protocol.

What Actually Happens When Evaluation Is Skipped

Outcome variability rises sharply when peptide therapy begins without a baseline evaluation.¹

Without pre-treatment IGF-1, fasting insulin, HbA1c, and condition-specific markers, there is no objective way to confirm therapeutic effect or detect adverse metabolic changes during peptide therapy.

Results from peptides are highly individual. Genetics, diet, lifestyle, organ function, and the specific protocol all influence outcomes.¹ A patient with subclinical hypothyroidism will have a blunted response to GH secretagogues until thyroid dysfunction is addressed. A patient with HOMA-IR above 2.0 requires a modified starting dose and dietary co-intervention.¹ Without these data points, dosing becomes guesswork, and maintenance protocols cannot be calibrated to objective response.

Maintenance is also a practical reality. Peptide benefits diminish when therapy is discontinued, similar to stopping any structured health regimen. Ongoing monitoring ensures that protocols are adjusted as the body responds and that maintenance phases are structured around measurable biomarker targets rather than subjective impression alone.

Meet Your Peptide Provider, Ellie Pranckevicius, FNP-BC

Ellie Pranckevicius is a board-certified Family Nurse Practitioner and the lead practitioner for peptide therapies and non-surgical aesthetics at Mirror Plastic Surgery. She earned her Bachelor’s in Health Science from Boston University on the premedical track, completed an aesthetics licensure program, and obtained both her Bachelor’s and Master’s in Nursing from the University of South Florida. Her clinical foundation includes four years in the Neuroscience ICU at Tampa General Hospital, where she developed deep expertise in physiology, metabolic health, and complex patient management. Ellie’s combination of esthetician training and advanced nursing credentials gives her a dual perspective on the aesthetic goals patients want to achieve and the clinical science required to get there safely.

Current Trends in Personalized Peptide Care at Mirror

Custom peptide stacks, which combine two or more peptides targeting complementary pathways, now represent the standard of care in supervised peptide medicine. Mirror Plastic Surgery’s Glow Stack (GHK-Cu, BPC-157, TB500), for example, addresses systemic inflammation, collagen and elastin production, and soft tissue repair at the same time. GLP-3R compounding represents a newer generation of incretin-class peptides reported to have fewer gastrointestinal side effects than earlier GLP-1 formulations and broader metabolic indications.

A 2026 narrative review in Frontiers in Endocrinology documented that unregulated performance-enhancing peptides modulating the GH–IGF-1 axis are associated with endocrine and metabolic disturbances when used without medical supervision. This finding reinforces the importance of batch-tested sourcing and physician oversight. Mirror Plastic Surgery sources peptides exclusively from reputable providers with documented batch testing for purity, identity, and accurate dosage, which is a critical quality control step given the non-FDA-regulated status of most peptide compounds.

How to Decide Whether Peptide Therapy Fits Your Goals

Individuals considering peptide therapy should weigh several practical and safety factors before moving forward.

• Safety and contraindication screening: Certain peptide classes carry absolute contraindications that only a thorough history and lab panel can identify. Proceeding without this step introduces risks that product quality alone cannot offset.
• Supervision model: The difference between a concierge model with ongoing lab monitoring and a one-time online consultation is clinically significant. Protocol adjustments based on 6–8 week IGF-1 rechecks, for example, require a provider relationship that continues beyond the initial prescription.
• Outcome variability: Results vary significantly by individual. Personalized protocols based on lab data and health history produce more consistent outcomes than population-average dosing.
• Maintenance requirements: Peptide benefits require ongoing management. Patients should enter therapy with a realistic understanding of maintenance protocols and the monitoring schedule needed to sustain results safely.

Common Misconceptions About Peptide Therapies

• Peptides are only for weight loss. Peptide therapies address a wide range of conditions including systemic inflammation, autoimmune diseases, post-surgical recovery, neurological health, energy and anti-aging, sexual wellness, and fertility. Weight management via GLP-3R compounding is one application among many.
• Peptides are supplements. Peptides are biologically active compounds that interact with specific receptors and signaling pathways. They are not inert supplements and require the same pre-treatment diligence as any prescription medication.
• Results are immediate and permanent. Initial improvements in inflammation or energy may appear within the first week for some protocols. Substantial changes in body composition, metabolic markers, or autoimmune status emerge over months and require ongoing management to sustain.¹
• Online peptides are equivalent to supervised protocols. A Viewpoint published in JAMA raised concerns about the surge in online injectable peptides and falling regulation behind their use.

Connect with Ellie to explore which peptide protocols match your unique health profile and wellness goals.

Frequently Asked Questions

Are peptides approved by the FDA?

Most peptides used in wellness and performance contexts are not FDA-regulated as drugs. They are used extensively in clinical and research settings worldwide, with studies spanning over a decade for many compounds. The primary risk often comes from obtaining them from unregulated sources without quality control, accurate dosing, or medical supervision. Mirror Plastic Surgery sources peptides exclusively from providers with documented batch testing and provides comprehensive medical oversight before, during, and after therapy.

What are the risks of using peptides without supervision?

Risks of unsupervised peptide use include receiving a product with incorrect identity or potency, missing a contraindication that makes a specific peptide dangerous for your health profile, developing subclinical side effects such as elevated liver enzymes or hormonal imbalances that go undetected without monitoring, and having no objective framework to determine whether the protocol is working. Serious documented adverse events, including pancreatitis, severe allergic reactions requiring hospitalization, and systemic inflammatory responses, have been reported in users of unregulated peptide products. Medical supervision with baseline and follow-up labs is the only reliable way to reduce these risks.

Will everyone see the same results with peptides?

No. Results from peptide therapy vary significantly from person to person based on genetics, baseline lab values, diet, lifestyle, the specific peptide protocol used, and whether underlying conditions such as thyroid dysfunction or insulin resistance have been identified and addressed.¹ This variation is exactly why a personalized evaluation, including medical history and lab results, is essential before any protocol begins. Mirror Plastic Surgery’s approach creates a custom protocol tailored to each individual’s physiology and goals rather than applying population-average dosing.

What happens if I stop taking peptides?

When peptide therapy is discontinued, the effects gradually diminish. For inflammation management, the immune dysregulation that was being modulated will likely return to its prior state. For GH secretagogue protocols, IGF-1 levels will decline back toward baseline. Continued use through a structured maintenance protocol is typically necessary to sustain the benefits achieved. Ellie works with each patient to establish realistic maintenance expectations and adjust protocols over time based on ongoing lab monitoring and symptom response.

Can peptide therapy be managed remotely?

Yes. Mirror Plastic Surgery offers the full consultation, prescription, and shipping process both in-person at the St. Petersburg, FL location and remotely across the United States, including Hawaii and Alaska. Patients receive direct 24/7 access to Ellie via text for ongoing support, questions, and refill requests, along with detailed instructions for reconstitution and self-administration, often accompanied by video demonstrations. Telemedicine follow-up appointments are available to review updated labs and adjust protocols as needed.

---

A thorough medical evaluation before personalized peptide treatment is not a formality. It is the mechanism by which safety is established, contraindications are identified, and protocols are individualized to produce measurable outcomes. The depth of that evaluation, the specificity of the lab panels ordered, and the continuity of monitoring throughout therapy distinguish a concierge medicine model from a one-size-fits-all approach. For individuals navigating chronic inflammation, autoimmune conditions, weight management, or anti-aging goals, the quality of the evaluation directly determines the quality of the outcome.

Disclaimer: Peptide therapies discussed on this page are not FDA-approved drugs for the indications described. They are not intended to diagnose, treat, cure, or prevent any disease. All protocols at Mirror Plastic Surgery are provided under the supervision of a licensed medical professional following individualized evaluation. This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before initiating any peptide therapy.

---